Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Escherichia coli Infections × Piperacillin, Tazobactam Drug Combination × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 2 Hematologic Neoplasms 2 Neoplasms, Plasma Cell 1 Lymphoma 1 Leukemia 1 Klebsiella Infections 1 Gram-Positive Bacterial Infections 1 Febrile Neutropenia 1 Escherichia coli Infections 1 Bacterial Infections 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡